VivoSim Labs, Inc.
VIVS
Positions held
Your positionsVIVS isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $2.94M | Enterprise value | $1.28M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | -0.24 | Beta | 1.49 | Dividend yield | 0.00% |
| Revenue growth | -51.4% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -153.3% |
| Profit margin | 0.0% | ROE | -3.4% | ROA | -89.5% | Debt / equity | — |
| Current ratio | 1.70 | Free cash flow | -$7.58M | Analyst recommendation | none | Mean target | — |
| 52w high | $3.41 | 52w low | $0.17 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | -15327.8% | -7967.5% | -10576.9% | -9410.7% | -7878.4% | — |
| Net income | -$1.3M | -$5.8M | -$2.7M | -$2.5M | -$2.8M | — |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Gross profit | — | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M |
| Operating income | -$2.8M | -$3.2M | -$2.8M | -$2.6M | -$2.9M | — |
- Revenue -55% vs prior quarter ($0.0M vs $0.0M).
- Gross margin 100% (was 100% prior quarter).
- Operating margin compressed to -15327.8%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $0.1M | $0.1M | $0.4M | — |
| Op margin | -8768.7% | -8761.1% | -13840.4% | -4792.2% | — |
| Net income | -$13.8M | -$2.5M | -$14.7M | -$17.3M | — |
| Gross margin | 100.0% | 96.5% | 100.0% | — | — |
| Gross profit | $0.1M | $0.1M | $0.1M | — | — |
| Operating income | -$11.5M | -$12.6M | -$15.1M | -$17.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
2026-09-01 · VivoSim Labs to Add Rat Liver Model to NAMkind Platform
2026-08-12 · VivoSim: Fiscal Q1 Earnings Snapshot
2026-08-07 · BC-Most Active Stocks
2026-08-06 · VivoSim Provides Financial and Listing Compliance Update
2026-07-21 · BC-Most Active Stocks
2026-07-21 · VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
2026-07-21 · VivoSim Enters China Market With Initial Preclinical Testing Contracts
2026-07-21 · VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
2026-07-16 · VivoSim Labs Prices $4 Million Private Placement of Stock, Warrants; Shares Fall Pre-Bell
Price (daily)
Full chart · RSI · MACD · patterns